Dry AMD Stem Cell Clinical Trial
The first patient in a clinical trial for dry age-related macular degeneration has been enrolled and transplanted with purified human neural stem cells. The HucCNS-SC cells protect host photoreceptors and preserve vision. The phase 1/11 trial will evaluate the safety and effectiveness of these cells as a treatment for dry AMD. 16 patients will be evaluated for a total of five years.